Antenatal Glucocorticoids Supplementation and Central Nervous System Development

Title:Antenatal Glucocorticoids Supplementation and Central Nervous System Development

Volume: 14 Issue: 2

Author(s): Diego Gazzolo, Laura D. Serpero, Alessandro Frigiola, Raul Abella, Alessandro Giamberti, Giovanni Li Volti and Fabrizio Michetti

Affiliation:

Keywords: Cardiovascular, CNS, glucocorticoids, MAP2, prematurity, S100B, Synaptophysin, Central Nervous System, Maternal antenatal therapy, CVS, SP-A, cardiomyocytes, Dexamethasone, GR, S100B Protein

Abstract: Maternal antenatal therapy with glucocorticoids (GC) is routinely used to prevent lung immaturity. The potential harmful effects on other organs, including in particular the central nervous system (CNS), are still controversial.

In the present review we aimed to investigate: i) the beneficial and detrimental effects of antenatal GC treatment in both human and animal models; ii) the potential usefulness of biochemical markers such as calcium binding proteins (S100B, synaptophysin) and cytoskeletal protein of neurons and dendrites (MAP2) in the perinatal period, and iii) whether the assessment of brain markers in different biological fluids could constitute a promising tool for the monitoring of CNS function and/or developmental in fetuses and newborns whose mothers assumed GC antenatally.

Cite this article as:

Gazzolo Diego, D. Serpero Laura, Frigiola Alessandro, Abella Raul, Giamberti Alessandro, Li Volti Giovanni and Michetti Fabrizio, Antenatal Glucocorticoids Supplementation and Central Nervous System Development, Current Drug Metabolism 2013; 14 (2) . https://dx.doi.org/10.2174/1389200211314020002